Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device

NCT03015909 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT03015909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03015909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device
Lead sponsor
LG Life Sciences
Phase
Phase 4
Overall status
Completed
Start date
August 11, 2016
Completion date
December 21, 2017
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure, growth hormone deficiency, infant, small for gestational age, short stature, idiopathic, turner syndrome